Pfizer, CornoaVac COVID-19 Vaccine Linked to Heart Inflammation Risk

A higher risk of carditis (a type of heart inflammation) has been associated with the COVID-19 vaccine developed by US drugmaker Pfizer and China's CoronaVac.

The findings, published in Annals of Internal Medicine, show a significant increased risk in adolescents after the second dose.

Myocarditis - Types, Causes, Symptoms, Complications, Treatment, Prognosis
Myocarditis is an inflammation of the heart muscle. It is caused due to the body’s immune system reacting against itself. It presents in various ways and is difficult to diagnose.

‘Patients who received Pfizer were three times more likely to experience carditis than unvaccinated patients.’

On the other hand, patients who received CoronaVac had a similar chance as unvaccinated patients to experience carditis.

Researchers from the University of Hong Kong also observed that risk increase associated with Pfizer's Covid vaccine was predominant in males and was more likely to be seen after the second dose.

"The vaccination strategies may need to continuously consider the risks and benefits for different sub-populations, rather than taking a aone-size-fits-all' approach," they suggested.

Quiz on Heart Attack
The risk factors that work behind the scene before a heart attack are familiar to many. But do you realize the extent to which your lifestyle choices are putting your life at risk? Can you identify a heart attack when it occurs? Take our quiz and find out.

Carditis is a rare inflammation of the heart often caused by bacterial, viral, and parasitic infections. Common subtypes of carditis include myocarditis, an inflammation of the heart muscle, and pericarditis, an inflammation of the outer lining of the heart.

Case reports of carditis after PfizerA vaccine vaccination have accrued globally.

Clinical Trial of Omicron-specific COVID-19 Vaccine
In healthy adults from 18 through 55 years of age, the pharma giant Pfizer and biotechnology company BioNTech have started clinical trials of an Omicron-based COVID-19 vaccine candidate.

The team studied 160 case patients (with carditis) and 1,533 control patients (without carditis) to examine the potential risk of carditis associated with vaccination with Pfizer vaccine or CoronaVac.

After conducting analyses, the team found 20 cases of carditis associated with Pfizer and seven associated with CoronaVac vaccination.

�Nocebo Effect� may be Behind COVID-19 Vaccine Symptoms
Researchers calculate that about two-thirds of common side-effects reported in COVID-19 vaccine trials are driven by the nocebo effect, in particular headaches and fatigue.

Cumulative incidence of carditis after vaccination was 0.57 per 100,000 doses of Pfizer and 0.31 per 100,000 doses of CoronaVac, demonstrating a very low absolute risk of carditis after vaccination.

However, none of the 20 case patients with carditis after Pfizer vaccination were admitted to the ICU or died within the observation period, compared with 14 of 133 unvaccinated patients admitted to the ICU and 12 deaths, the researchers said.

Source-IANS